Cencora Inc (COR) Stock Forecast & Price Target

Cencora is positioned favorably because its dominant domestic wholesale footprint, with over 90% industry share alongside McKesson and Cardinal Health, supports resilient scale in branded, generic, and specialty pharmaceutical distribution. Its expanding vertical integration into patient support, data analytics, specialty logistics, and commercialization services should lift the mix toward higher-margin offerings, while biosimilar adoption can be meaningfully accretive as 6-8% margins compare with roughly 1% on branded products. Although drug-pricing policies and PBM steerage create headwinds, specialty drug volume growth, accelerated biosimilar penetration, and the 2021 Alliance Healthcare acquisition strengthen the case for stronger topline growth and modest margin expansion.

Cencora is facing a cautious fundamental outlook because its core pharmaceutical distribution business remains exposed to low-single-digit gross margins, while IRA and MFN pricing pressures could slow Pharma segment growth to mid-single digits and compress economics as ~$28B of Medicare drug spend becomes subject to 40-60% price cuts in 2028. The company also faces elevated customer concentration and contract renewal risk, since losses to McKesson or Cardinal Health could materially reduce revenue visibility and distribution volumes, and its international operations through World Courier and Alliance Healthcare add earnings volatility from currency, regulatory, and geopolitical risks. Although specialty growth and services offer some support, the portfolio appears less diversified than peers, with competitors estimated to have ~100-~200bps more topline growth in 2028 and ~300-~900bps more OI growth.